Paper4698309
Infantile type of so-called neuronal ceroid-lipofuscinosis. 1. A clinical study of 15 patients.
Santavuori P and 3 others. J Neurol Sci, 1973. Cited by 157 papers, by iCite.
Cite this record
ConductScience Library. Infantile type of so-called neuronal ceroid-lipofuscinosis. 1. A clinical study of 15 patients. Papers, record 4698309. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/4698309
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Infantile type of so-called neuronal ceroid-lipofuscinosis. 1. A clinical study of 15 patients.
- PubMed
Topics14
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Lipidoses | Major topic |
| Age Factors | |
| Brain | |
| Cerebrospinal Fluid Proteins | |
| Child | |
| Child, Preschool | |
| Electroencephalography | |
| Electromyography | |
| Electroretinography | |
| Female | |
| Humans | |
| Male | |
| Pigments, Biological | |
| Retina |
Source PubMed
Cited by45
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 157 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 41977268 | Systemic AAV9 Gene Therapy Mitigates Neuromuscular Junction Degeneration and Muscle Atrophy in a Mouse Model of CLN1 Disease. | Int J Mol Sci | 2026 | https://conductscience.org/library/papers/41977268 | PubMed |
| 41466111 | Limited therapeutic efficacy of N-acetyl-L-leucine in a mouse model of CLN1 disease. | Sci Rep | 2025 | https://conductscience.org/library/papers/41466111 | PubMed |
| 40682271 | AAV-delivered PPT1 provides long-term neurological benefits in CLN1 mice and achieves therapeutic levels in sheep brain. | Mol Ther | 2025 | https://conductscience.org/library/papers/40682271 | PubMed |
| 39813314 | Gene therapy ameliorates bowel dysmotility and enteric neuron degeneration and extends survival in lysosomal storage disorder mouse models. | Sci Transl Med | 2025 | https://conductscience.org/library/papers/39813314 | PubMed |
| 39695089 | GABAAR-PPT1 palmitoylation homeostasis controls synaptic transmission and circuitry oscillation. | Transl Psychiatry | 2024 | https://conductscience.org/library/papers/39695089 | PubMed |
| 38964324 | Retinal cells derived from patients with DRAM2-dependent CORD21 dystrophy exhibit key lysosomal enzyme deficiency and lysosomal content accumulation. | Stem Cell Reports | 2024 | https://conductscience.org/library/papers/38964324 | PubMed |
| 36438942 | Top-down and bottom-up propagation of disease in the neuronal ceroid lipofuscinoses. | Front Neurol | 2022 | https://conductscience.org/library/papers/36438942 | PubMed |
| 36285626 | The Finnish genetic heritage in 2022 - from diagnosis to translational research. | Dis Model Mech | 2022 | https://conductscience.org/library/papers/36285626 | PubMed |
| 34135943 | Transcriptome Profiling Analysis of the Testis After Eyestalk Ablation for Selection of the Candidate Genes Involved in the Male Sexual Development in Macrobrachium nipponense. | Front Genet | 2021 | https://conductscience.org/library/papers/34135943 | PubMed |
| 33390903 | Electrophysiological Profile Remodeling via Selective Suppression of Voltage-Gated Currents by CLN1/PPT1 Overexpression in Human Neuronal-Like Cells. | Front Cell Neurosci | 2020 | https://conductscience.org/library/papers/33390903 | PubMed |
| 33365208 | Advances in the Treatment of Neuronal Ceroid Lipofuscinosis. | Expert Opin Orphan Drugs | 2019 | https://conductscience.org/library/papers/33365208 | PubMed |
| 33315139 | [Ophthalmological manifestations of neuronal ceroid lipofuscinoses (NCL) : NCL as diseases of brain and retina-the role of ophthalmologists]. | Ophthalmologe | 2021 | https://conductscience.org/library/papers/33315139 | PubMed |
| 33242182 | Neuronal Ceroid Lipofuscinosis: Potential for Targeted Therapy. | Drugs | 2021 | https://conductscience.org/library/papers/33242182 | PubMed |
| 32841420 | Spinal manifestations of CLN1 disease start during the early postnatal period. | Neuropathol Appl Neurobiol | 2021 | https://conductscience.org/library/papers/32841420 | PubMed |
| 31578378 | Mice deficient in the lysosomal enzyme palmitoyl-protein thioesterase 1 (PPT1) display a complex retinal phenotype. | Sci Rep | 2019 | https://conductscience.org/library/papers/31578378 | PubMed |
| 31025705 | Cln3-mutations underlying juvenile neuronal ceroid lipofuscinosis cause significantly reduced levels of Palmitoyl-protein thioesterases-1 (Ppt1)-protein and Ppt1-enzyme activity in the lysosome. | J Inherit Metab Dis | 2019 | https://conductscience.org/library/papers/31025705 | PubMed |
| 28733362 | Loss of Cln5 causes altered neurogenesis in a mouse model of a childhood neurodegenerative disorder. | Dis Model Mech | 2017 | https://conductscience.org/library/papers/28733362 | PubMed |
| 28673981 | Synergistic effects of treating the spinal cord and brain in CLN1 disease. | Proc Natl Acad Sci U S A | 2017 | https://conductscience.org/library/papers/28673981 | PubMed |
| 28266544 | Misrouting of v-ATPase subunit V0a1 dysregulates lysosomal acidification in a neurodegenerative lysosomal storage disease model. | Nat Commun | 2017 | https://conductscience.org/library/papers/28266544 | PubMed |
| 28213849 | Widespread Expression of a Membrane-Tethered Version of the Soluble Lysosomal Enzyme Palmitoyl Protein Thioesterase-1. | JIMD Rep | 2017 | https://conductscience.org/library/papers/28213849 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- References
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/4698309
GET https://conductscience.org/api/papers/v1/4698309/cited_by?page=2